IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
IBI110 is an investigational drug under evaluation for treatment of small cell lung cancer.
The purpose of the study was to assess the Efficacy and Safety of IBI110 in combination with
Sintilimab and chemotherapy with untreated ES-SCLC.